艾伯维公司旗下试验性精神分裂症药物未能达到两项中期试验的主要目标,导致公司股价在今天盘前就大跌近14%。
作为一家主攻抗癌以及免疫类疾病药物研发的大型生物制药公司,这一消息无疑让业界和投资人大跌眼镜。新药研发是艾伯维公司未来长期增长的核心动力之一,此次重磅新品失利打击了大家对该公司前景的信心。
精神分裂症药物属于一个利润丰厚的全球市场,按照预期如果该药物一旦上市将为艾伯维公司贡献数十亿美元年收入。现在进展受阻,市场自然会对公司未来盈利能力产生质疑,从而体现在股价暴跌上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.